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Abstract
Introduction:  Multiple endocrine neoplasia type 1 (MEN-1) patients are prone to develop
carcinoid tumors. Few cases report the development of gastrointestinal carcinoid tumors in
patients with MEN-1 syndrome related tumors. This is the first paper to report the occurrence of
an intestinal carcinoid tumour in association with a pituitary adenoma.
Case presentation: A sixty eight year old female presented with intestinal obstruction four years
after transphenoidal pituitary resection for pituitary adenoma. During surgical exploration and lysis
of adhesions, we accidentally discovered an intestinal carcinoid tumour. Resection of the involved
small bowel segment and the draining lymph nodes was undertaken. Postoperative follow up
showed no biochemical or radiological evidence of residual tumor.
Neuroendocrine tumors (NETs) may occur as part of familial endocrine cancer syndromes
including MEN-1. It is recommended that clinicians search thoroughly for MEN-1 in patients
presented with NETs, however, there is no current consensus for screening patients suspected to
have MEN-1 to rule out NET.
Conclusion: We recommend screening patients suspected to have any familial type of endocrine
tumors for the presence 32of NET.
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Introduction
Multiple endocrine neoplasia type 1 (MEN-1) is an auto-
somal dominant disease with a broad spectrum of clinical
manifestations [1,2]. Though parathyroid hyperplasia,
gastroenteropancreatic neoplasia, pituitary tumours and
adrenal adenoma are the most frequent disease pheno-
types [1,2], patients with MEN-1 are also liable to develop
subcutaneous lipomas, gastrointestinal, bronchial, and
thymic carcinoid tumours [3,4].
There are few case reports of the development of gastroin-
testinal carcinoid tumors in patients diagnosed with
MEN-1 syndrome related tumors. Carcinoid tumor in
these cases was located in the duodenum [5], and the
stomach [6]. This is the first paper to report the occurrence
of an intestinal carcinoid tumour in association of a pitu-
itary adenoma.
Case presentation
Our patient was a 68 year old African American female
who developed diffuse abdominal pain, associated with
nausea and bilious vomiting, 24 hours prior to her emer-
gency room visit. The pain was localized to the epigastric
region and had a progressive course. Her last bowel move-
ment was reported as four days prior and she denied any
recent weight loss, wheezing, flushing, palpitation or
change in bowel habits.
The patient's past medical and surgical history included
hypertension, hyperlipidemia, total abdominal hysterec-
tomy and bilateral salpingoophorectomy secondary to
fibroids.
The patient also reported a history of progressive loss of
vision ten years earlier that was investigated by brain MRI
after an extensive ophthalmological evaluation. The MRI
showed a pituitary tumor and the patient benefited from
a transphenoidal pituitary tumor resection. The patholog-
ical examination revealed a chromophobic pituitary ade-
noma.
The patient had a strong family history of cancer. Her
father died from colon cancer, a brother died from
esophageal cancer, an uncle died from brain tumor, one
aunt had been diagnosed with breast cancer and one aunt
with gastric cancer.
Upon physical exam, the patient had a tense, distended
abdomen, with a well healed paramedian incision and no
bowel sounds. There was non localized diffuse tenderness
with positive rebound and voluntary guarding. Rectal
examination revealed no masses and an empty vault. Lab-
oratory values revealed no leukocytosis, however the lactic
acid level was elevated. A computed tomography scan of
the abdomen revealed a small bowel obstruction. Subse-
quently, the patient was decompressed with a nasogastric
tube and fluid resuscitation, and brought to the operating
room for an exploratory laparotomy. Intraoperatively,
there was significant small bowel congestion with no
necrosis. One adhesive band was found and lysed at the
mid jejunum where it was fixed to the pelvic wall. The
bowel was thoroughly inspected to look for any other
points of obstruction or abnormalities. A serosal lesion
was found on the surface of the jejunum ten centimeters
from the adhesion (Figure 1). Also a suspicious hard
draining mesenteric lymph node was seen. The serosal
lesion, and the suspicious lymph node were both resected
(Figure 2), and sent for pathologic determination.
Postoperatively, the patient did well, however, the patho-
logical evaluation of both the serosal lesion and the
mesenteric lymph node revealed carcinoid tumor.
Three days later, the patient was brought back to the oper-
ating room for exploratory laparotomy and small bowel
resection. During the surgery, there was no intestinal
lesion noted, and about 15 cm of small bowel on each
side from the previous serosal lesion was resected with its
corresponded mesentery (Figure 3). One enlarged and
firm mesenteric lymph node, included in the specimen
was marked with a stitch.
The pathological examination of the specimen revealed a
carcinoid tumor approximately 0.4 cm in greatest dimen-
sion, penetrating subserosa five centimeters from the pre-
viously resected serosal lesion (Figure 4). A metastatic
carcinoid tumor was seen in three out of 17 lymph nodes
(Figure 5) including the one marked with the stitch. The
surgical resection margins were negative.
Small bowel serosal lesion Figure 1
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During the postoperative inpatient period, a 24 hour
urine 5-Hydroxyindole Acetic Acid (5-HIAA) was within
normal value and no focal area of increase uptake was
noted on an octreotide scan.
There was no postoperative morbidity, and the patient
was followed as an outpatient at two and six month inter-
val. During these follow up visits, the patient reported
feeling better and denied any weight loss, wheezing, flush-
ing, palpitations or diarrhea.
A postoperative CT scan of the chest abdomen and pelvis
six months after the surgery, revealed no evidence of
recurrent disease, and no intra abdominal masses. A
repeat octreotide scan at six months after the surgery did
not show any area of increase uptake. Chromogranin A
level was followed, and was decreasing from 142 ng/ml at
two months post resection, to 64 ng/ml at six months post
resection.
Discussion
Neuroendocrine tumors (NETs) constitute a heterogene-
ous group of neoplasms with common characteristics and
biological features. NETs were previously referred as apu-
domas, by Pearse in 1969 [7], when he described peptide-
secreting endocrine cells that share an ability to take up
precursors of biologically active amines, to produce active
Lymph node with H&E staining ×4 magnification: Carcinoid  metastases Figure 5
Lymph node with H&E staining ×4 magnification: Carcinoid 
metastases.
Small bowel resection segment Figure 3
Small bowel resection segment.
Resected serosal lesion and suspicious mesenteric lymph  node Figure 2
Resected serosal lesion and suspicious mesenteric lymph 
node.
Small Bowel with H&E staining × 20 magnification: Carcinoid  tumor penetrating the subserosa Figure 4
Small Bowel with H&E staining × 20 magnification: Carcinoid 
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amine through subsequent intracellular decarboxylation,
hence APUD (amine precursor uptake and decarboxyla-
tion).
This widespread phenomenon initially reported by Pearse
himself in 1964, when describing the calcitonin-secreting
parafollicular C cells of dog thyroid, was also found in
other peptide hormone-secreting cells, for example in the
corticotrophs of the anterior pituitary gland and in the b-
cells of the endocrine pancreas. Currently, APUD cells
including more than 40 cell types are best referred as a dif-
fuse neuroendocrine system.
Primary gastroenteropancreatic NETs can be asympto-
matic but may present with obstructive symptoms, and
carcinoid syndrome when tumors metastases to the liver
with the subsequent release of vasoactive substances
responsible of the classical picture of flushing, diarrhea,
lacrimation, palpitations, and wheezing.
Midgut carcinoid tumours have a wide range of presenting
signs including abdominal pain, nausea and vomiting,
weight loss, diarrhea, gastrointestinal bleeding and carci-
noid syndrome. However, significant number are inciden-
tally discovered in resected surgical specimens when
surgery had been undertaken for other intra abdominal
disease [8].
Though the majority of NETs occur spontaneously, NETs
may occur also as part of complex familial endocrine can-
cer syndromes such as MEN-1, MEN-2, Neurofibromato-
sis type 1(NFT type 1), Von Hippel Lindau disease, and
Carney's Complex [9-11].
The incidence of MEN-1 in gastroenteropancreatic NETs
was reported to range from 30% in gastrinoma to virtually
none in gut carcinoid [12]. However, it is recommended
to search thoroughly for MEN-1, MEN-2 and NF1 in all
patients presented with NETs by obtaining family history,
clinical examination, appropriate biochemical and radio-
logical investigations and genetic testing [13].
At the same time, surveillance for persons known to have
MEN-1 to rule out NET was previously suggested [14]. The
current follow up recommendations for patients known
to have MEN-1 syndrome start at age of ten with yearly
physical examination, laboratory tests including fasting
serum gastrin, calcium, albumin, pancreatic polypeptide
levels, and abdominal CT or MRI. Every other year these
patients should also have a head MRI and prolactin level
[14,15]. Currently, screening for NETs is not mandatory in
these patients.
For persons suspected to have MEN-1, including those
with a first degree affected relative but without gene test-
ing, and members of a clinical group at risk, the current
recommendations do not include screening for NETs [14].
This case report is the first to report the occurrence of an
intestinal NET in a patient previously documented to have
a pituitary adenoma. In our patient, intestinal NET was
found in a specimen taken during abdominal surgery for
other reason. Surgical resection of the tumor with postop-
erative negative octreotide scan, decreasing chromogranin
A level, and 5-HIAA within normal values reflects a favo-
rable prognosis.
We believe that screening patients suspected to have any
familial type of endocrine tumors for NETs, could help
early diagnosis in asymptomatic patients, and offer them
the best chance for curative resection. The screening pro-
tocol can possibly include biochemical tests including 5-
HIAA, chromogranin A, radiological evaluation including
an octreotide scan, and endoscopic examination includ-
ing endoscopic ultrasound. Screening large numbers of
patients with either documented or suspected MEN-1 syn-
drome using biochemical, radiological and endoscopic
tests will help to select the best, and the most reliable
screening modality. A follow up of these patients could
show a potential beneficial effect related to the early
detection of NETs diagnosed by this screening protocol.
Conclusion
A critical component in the diagnosis of a neuroendocrine
tumor is suspicion of its presence. We believe that screen-
ing patients suspected of having any familial type of endo-
crine tumors for NETs could help early diagnosis in
asymptomatic patients and offers these patients the best
chance to have a curative resection. Further studies are
required to investigate the best screening modality.
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